Abstract: The present invention provides pyrazole derivatives, e.g., a compound of Formula (I), and their uses in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

Abstract: A non-magnetic method is disclosed for determining presence and/or concentration of at least one radical species in a sample.

Abstract: The present invention relates to a method for forming a protective coating on a plant tissue following the consecutives steps of: (a) providing a plant having an external surface, wherein a portion of the external surface includes an exposed surface; (b) applying a first aqueous solution that contains a crosslinking agent to the external surface of the plant; and (c) applying to the external surface of the plant a second aqueous solution that contains a polysaccharide which is susceptible to crosslinking by the crosslinking agent, thereby forming a protective coating on the exposed surface of the plant. Further provided is a postharvest plant matter that includes a first segment covered by natural skin, and a second segment having an exposed surface that is coated by a protective coating that contains a polysaccharide with the first segment being essentially free of the protective coating.

Abstract: A method of generating an induced trophoblast stem cell (iTSC) from a human cell is provided. Accordingly there is provided a method comprising expressing within a human cell GATA3 and OCT4 transcription factors, under conditions which allow generation of an iTSC from the cell. Also provided is a method of rejuvenating and/or de-differentiating a human cell. Also provided are nucleic acid constructs, protein preparation, isolated human cells, human iTSCs, rejuvenated cells and de-differentiated cells.

Abstract: The invention provides cannabinoid derivatives, methods of their preparation, compositions comprising them and uses thereof in the treatment of inflammation and/or pain and/or obesity.

Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.

Abstract: The present invention provides nanoparticle carriers of active agents which are functionalized by stimuli-responsive conjugation with DNA-nano structures, methods and processes for their preparation, compositions comprising them and uses thereof in methods of treating diseases, disorders and symptoms thereof.

Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

Abstract: Provided are in-vitro methods and devices for sustaining a synchronized circadian rhythm in cells of a cell culture by exposing the cells to a continuous flow of medium and to at least two stimuli provided in an oscillating manner with a periodicity of 24±4 hours, wherein a first stimulus and a second stimulus of said at least two stimuli are distinct, wherein said first stimulus is provided in a first time period and reaches a first peak in a first peak time period, and wherein a second stimulus is provided in a second time period and reaches a second peak in a second peak time period, and wherein an interval between end of time period of said first peak and beginning of said time period of said second peak is at least about 2 hours.

Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.

Abstract: A method of increasing milk secretion of a predetermined milk component from a tissue culture comprising mammary epithelial cells (MECs) is provided. The method comprising admixing into a medium composition comprising the tissue culture, a biologically effective concentration of a composition selectably operable to increase the secretion of the predetermined components, the composition comprising at least one agent selected from the group consisting of oleic acid, beta-hydroxybutirate (BHBA) and a phenolic composition, wherein the agent is not an ethanol extract of P. lentiscus; and when the agent comprises oleic acid it comprises at least two of the agents.

Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.

Abstract: Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.

Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).

Abstract: A spin-selective conduction structure comprises a crystal having a monolayer of metal atoms between two layers of chiral organic molecules. Each metal atom is coupled to two chiral organic molecules, one at each layer, wherein a chirality of organic molecules in one of the two layers is the same as a chirality of organic molecules in another one of the two layers.

Abstract: A method of modifying a glycosylation pattern of a polypeptide-of-interest in a plant or plant cell is provided. The method comprising expressing in a plant or plant cell transformed to express at least one glycosidase in a subcellular compartment, a nucleic acid sequence encoding the polypeptide-of-interest, such that the at least one glycosidase and the polypeptide-of-interest are co-localized to the subcellular compartment of the plant or plant cell, thereby modifying the glycosylation pattern of the polypeptide-of-interest in the plant or plant cell.

Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.

Abstract: Methods, compositions and kits for reducing renal tissue toxicity in a subject caused by a kidney damaging agent are provided. The methods comprise administering to the subject: (i) a kidney damaging agent; (ii) a PPARA activator; and (iii) an inhibitor of a cellular pathway selected from the group consisting of C/EBP, PPARG, ER stress, GLUT2 and SGLT1/2; or (i) a kidney damaging agent; (ii) a SGLT2 inhibitor; and (iii) a PPARA activator, a C/EBP inhibitor, a PPARG inhibitor, or an ER stress inhibitor.

Abstract: The invention disclosed herein concerns a novel class of compounds suitable for the treatment of neurodegenerative diseases, such as Parkinson’s Disease.

Abstract: Provided is a perovskite-based photovoltaic device including a layered scaffold material and at least one perovskite material interpenetrating the layered scaffold, wherein the at least one perovskite layer is removable and regenerable.